•  
  •  
 

Abstract

Introduction. Antituberculosis (ATT) induced hepatotoxicity is commonly found among HIV/AIDS patients. Several risk factor related to drug-induced hepatotoxicity such as alcoholism, hepatitis B or hepatitis C infection, abnormal baseline aminotransferase/bilirubin, poor nutritional status and concomitant hepatotoxic drugs consumption, are usually found in these patients. This study was conducted to evaluate risk factor of ATT-induced hepatotoxicity in HIV/AIDS patients. Methods. This is a case control retrospective study with matching of age, sex, antituberculosis regimen, and alcohol consumption. Risk factors evaluated are hepatitis C and hepatitis B coinfection, concomitant hepatotoxic drugs consumption, abnormal baseline aminotransferase and or bilirubin. Results. We collected data of 33 cases and 33 controls We found 82% subjects in case group and 76% subjects in control group have hepatitis C coinfection; 18% subjects in case group and 6% subjects in control group have hepatitis B coinfection. Fifty four point five percent (54.5%) subjects in case group and 42.4% subjects in control group consume other hepatotoxic drugs. Elevated baseline ALT level was found in 51.5% subjects in case group and 12% subject in control group. Bivariate analysis showed that the risk of hepatotoxicity was higher in patients with elevated baseline ALT level (OR=7.5; 95% CI 1,72- 32,80; p < 0,05). Conclusions. Elevated baseline ALT level will increase antituberculosis drug induce hepatotoxicity risk up to 7.5 times. There were no association between hepatitis C, hepatitis B, concomitant hepatotoxic drugs consumption and antituberculosis drug-induced hepatotoxicity in HIV/AIDS patients.

References

1. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV co-infection. PLoS Pathog. 2012;8(2):e1002464. 2. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy. JAMA. 1999;281(11):1014-8. 3. Leung CC, Law WS, Chang KC, Tam CM, Yew WW, Chan CK, et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest. 2003;124(4):2112-8. 4. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J. 2005;26(3):462-4. 5. Burman WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers. Am J Respir Crit Care Med. 2001;164(7):1112-3. 6. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991;99(2):465-71. 7. Bernida I, Suryatenggara W, Mangunegoro H. Pengaruh cara pemberian obat antituberkulosis terhadap fungsi hati dan konversi sputum pada penderita tuberkulosis paru. Paru. 1994;14(2):17-24. 8. Chang KC, Leung CC, Yew WW, Tam CM. Standard antituberculosis treatment and hepatotoxicity: do dosing schedules matter? Eur Respir J. 2007;29(2):347-51. 9. Dienstag LJ, Isselbacher KJ. Toxic and drug induced hepatitis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal Medicine. 17th ed. United States of America: McGraw Hill Company; 2008. p.1949-54. 10. Sherlock S, Dooley J. Drug and the liver. In: Sherlock S, Dooley J, editors. Diseases of the Liver and Biliary System. 11th ed. New York: Oxford University Press; 2000. p.483-97. 11. Lee WM, Schiodt FV. Drug induced liver disease. In: Yamada T, editor. Texbook of Gastroenterology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p.2352-65. 12. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology. 2006;11(6):699-707. 13. Tostmann A, Boeree MJ, Aarnoutse RE, De Lange MCM, Van der Ven AJAM, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up to date review. J Gastroenrol Hepatol. 2008;23(2):192- 202. 14. Saukhonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935-52. 15. Pukenyte E, Lescure FX, Rey D, Cabaud C, Hoen B, Chavanet P, et al. Incidence of and risk factors for severe liver toxicity in HIVinfected patients in anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2007;11(1):78-84. 16. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157(6 pt1):1871-6. 17. Tostmann A, Boeree MJ, Harries AD, Sauvageot D, Banda HT, Zijlstra EE. Antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pumonary tuberculosis patients in Malawi. Trop Med Int Health. 2007;12(7):852-5. 18. Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest. 2007;131(3):803-8. 19. Padmapriyadarsini C, Chandrabose J, Victor L, Hanna LE, Arunkum. Hepatitis B or hepatitis C co infection in individuals infected with human immunodeficiency virus and effect of anti-tuberculosis drugs on liver function. J Postgrad Med. 2006;52(2):92-6. 20. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol. 1997;12(1):87-91. 21. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest. 2005;127(4):1304-11. 22. Wong WM, Wu PC, Yuen MF. Antituberculosis drug related liver dysfunction in chronic hepatitis B infection. Hepatology. 2000;31(1):201-6. 23. Cho HJ, Koh WJ, Ryu YJ, Ki CS, Nam MY, Kim JW, et al. Genetic polymorphism of NAT2 and CYP2E1 associated with antituberculosis drug induced hepatotoxicity in korean patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2007;87(6):551-6. 24. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, et al. Cytochrome P450 genotype and the susceptibility to antituberculosis drug induced hepatitis. Hepatology. 2003;37(4):924-30. 25. Mahmood K, Hussain A, Jairamani KL, Talib A, Abbasi BU, Salkeen S. Hepatotoxicity with antituberculosis drugs: the risk factors. Pak J Med Sci. 2007;23(1):33-8.

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.